Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone

Osteoporosis International

Volumn 7, Issue SUPPL. 1, 1997, Pages 29-34

  McDonnell, D P ^a   Norris, J D ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; FULVESTRANT; RALOXIFENE; TAMOXIFEN;

BONE ATROPHY; CELL NUCLEUS; CONFERENCE PAPER; DNA RESPONSIVE ELEMENT; DRUG MECHANISM; HUMAN; LIGAND BINDING; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

EID: 0030977177     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf01674810     Document Type: Conference Paper

References (43)

1. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-30.
2. Smith DF, Toft DO. Steroid receptors and their associated proteins. Mol Endocrinol 1993;7:4-11.
3. Beekman JM, Allan GF, Tsai SY, Tsai M-J, O'Malley BW. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 1993;7:1266-74.
4. McDonnell DP, Nawaz Z, O'Malley BW. In situ distinction between steroid receptor binding and transactivation at a target gene. Mol Cell Biol 1991;11:4350-5.
5. Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988;55:145-56.
6. Ing N, Beekman J, Tsai S, Tsai M-J, O'Malley B. Members of the steroid hormone receptor superfamily interact with TMIIB (S300-II). J Biol Chem 1992;267:17617-23.
7. Onate SA, Tsai S, Tsai M-J, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-7.
8. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 1944;264:1455-8
9. Cavaillès V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ, Parker MG. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J 1995;14:3741-51.
10. Elliston J, Fawell S, Klein-Hitpass L, Tsai S, Tsai M-J, Parker M, O'Malley B. Mechanism of estrogen receptor-dependent transcription in a cell-free system. Mol Cell Biol 1990;10:6607-12.
11. Klein-Hitpass L, Tsai SY, Weigel NL, Allan GF, Riley D, Rodriguez R, Schrader WT, Tsai M-J, O'Malley BW. The progesterone receptor stimulates cell-free transcription by enhancing the formation of a stable preinitiation complex. Cell 1990;60:247-257.
12. Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic nude mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988;30:311-4.
13. Love RR, Wiebe DA, Newcombe PA, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991;115:860-4.
14. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC. et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
15. Jordan VC. The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 1992;70:977-82.
16. McDonnell DP, Lieberman BA, Norris J. Development of tissue-selective estrogen receptor modulators. In: Baird DT, Schutz G, Krattenmacher R (ed) Organ-selective actions of steroid hormones, vol 16. Berlin: Springer, 1995:1-28.
17. McDonnell DP, Clemm DL, Herman T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995;9:659-69.
18. Draper MW, Flowers DE, Huster WJ, Neild JA. Effects of raloxifene (LY 139481 HCL) on biochemical markers of bone and lipid metabolism in healthy post-menopausal women. Aalborg: Handelstrykkeriet, 1993.
19. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJS, Glasebrook AL, Termine JD. Estrogen and raloxifene stimulate transforming growth factor-ß3 gene expression in rat bone: potential mechanism for estrogen- or raloxifene mediated bone maintenance. Endocrinology 1996;137:2075-84.
20. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 1996;10:119-31.
21. Clark JH, Peck EJ. Female sex steroids: receptors and function. vol 14. Berlin: Springer, 1979.
22. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB et al. Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30.
23. Meyer ME, Pornon A, Ji J, Bocquel MT, Chambon P, Gronemeyer H. Agonist and antagonist properties of RU486 on the functions of the human progesterone receptor. EMBO J 1990;9:3923-32.
24. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443-56.
25. Gibson MK, Nemmers LA, Beckman WCJ, Davis VL, Curtis SW, Korach KS. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 1991;129:2000-10.
26. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahh W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 1995;92:4206-10.
27. Wrenn CK. Katzenellenbogen BS Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J Biol Chem 1993;268:24089-98.
28. Norris J, Fan D, Aleman C, Marks JR, Futreal A, Wiseman RW, et al. Identification of a new subclass of alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem 1995;270:22777-82.
29. McDonnell DP, Clemm DL, Imhof MO. Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors. Semin in Cancer Biol 1994;5:503-13.
30. Danielian PS, White R, Lees JA, Parker MG. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 1992;11:1025-33.
31. Norris J, Fan D and McDonnell DP. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of taxoxifen mixed agonist activity. Molecular Endocrinology 1996; 10:1605-1616.
32. Chen HK, Ke HZ, Ma YF, Crawford DT, Pirie CM, Simmons HA, et al. Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats. Bone 1995;17:175-9.
33. Willson TM, Henke BR, Momtahen TM, Charifson PS, Batchelor KW, Lubahn DB, Moore LB, Oliver BB, Sauls HR and Triantafillou JA. 3-[4-(1,2-Diphenylbut-1-enyl-phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 1994;37:1550-1552.
34. Chow J, Thobias JH, Colston KW, Chambers TJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest 1992;89:74-8.
35. Dukes M, Chester R, Yarwood L, Wakeling AE. Effects of a non-steroidal pure antiestrogen, ZM 189,154, on oestrogen target organs of the rat including bones. J Endocrinol 1994; 141:335-41.
36. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992;89:4037-41.
37. Dauvois S, White R, Parker MG. The antiestrogen ICI 182,780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377-88.
38. Parker MG. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993;26:131-137.
39. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990;87:6883-7.
40. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257:88-91. s
41. Stein B, Yang M. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPß. Mol Cell Biol 1995;15:4971-9 .
42. Ray A, Prefontaine KE, Ray P. Down-regulation of interleukin-6 gene expression by 17-ß-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 1994;269:12940-6.
43. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.